At a glance
ClinicalIndex Comparison RecordN/ACompleted· 403 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Special Investigation (All Cases Investigation in Patients With Ankylosing Spondylitis)
In Brief
An observational study for Ankylosing Spondylitis. Completed, enrolled 403 participants across 194 sites.
Detailed Summary
This study of adalimumab (Humira) will be conducted to clarify the following with regard to the treatment of ankylosing spondylitis with this drug: * Unknown adverse drug reactions (especially important adverse drug reactions) * Incidence and conditions of occurrence of adverse reactions in the clinical setting * Factors that may affect the safety and effectiveness of Humira
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAnkylosing Spondylitis
CountriesJapan
Collaborators--
Timeline
N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2010
First PostedApr 2011
Primary CompletionDec 2017
TodayJul 2026
First PostedApr 5, 2011
Enrollment StartOct 27, 2010
Primary CompletionDec 28, 2017
TodayJul 2, 2026
Enrollment to primary: 7.2 yearsPosted 15.2 years ago